Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 52Carcinoma, Non-Small-Cell Lung 28Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 24Stomach Neoplasms 19Recurrence 18Multiple Myeloma 18Carcinoma, Hepatocellular 18Neoplasm Metastasis 17Ovarian Neoplasms 15Lung Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 11Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

fluorodopa F 18 3Metformin 3Clomiphene 2pasireotide 1dapagliflozin 1amino-acid, glucose, and electrolyte solution 1Surveys and Questionnaires 1Sugars 1Solutions 1Saline Solution 1Pioglitazone 1Insulin 1Injections 1Diazoxide 1Amino Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hyperinsulinism × Injections × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡